Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

NCT04025216 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT04025216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04025216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1
Overall status
Terminated
Start date
October 10, 2019
Completion date
December 2, 2022
Enrollment
16 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, multiple myeloma, non-small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer